Cnsc-60. Synergistic Immunomodulation Through Dual Antibody Therapy Targeting Cd47 and Cd24 for Enhanced Antitumor Immunity in Glioblastoma
Year: 2024
Type: conference-abstract
Abstract: Tumor cell phagocytosis by antigen-presenting cells (APCs) plays a pivotal role in fostering antitumor immunity. However, glioblastoma, known for its evasive strategies, exploits key phagocytosis checkpoints, including CD47, CD24, and beta-2-microglobulin. While mono-treatment targeting CD47 blockade has shown some antitumor responses in glioma, prolonged tumor-suppressing ability and significant extension of survival remain elusive. In this study, we combine anti-CD47 and anti-CD24 antibody treatments, unveiling a synergistic effect in promoting tumor cell phagocytosis. This enhanced phagocytosis profile triggers the activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway in APCs, thereby facilitating efficient T cell priming. This orchestrated interplay between innate and adaptive antitumor immunity not only attenuates glioblastoma growth and extends overall survival. These findings illuminate a promising avenue for harnessing phagocytosis modulation as a strategic approach to treat challenging tumors equipped with multiple immune checkpoints.
Source: Neuro-Oncology
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4404237807